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Abstract 
  BACKGROUND: Leptin and adiponectin are two adipose tissue hormones and their association 
with the incidence of cardiovascular diseases is under evaluation. The aim of this study was to 
determine the relationship of leptin and adiponectin with coronary artery diseases. 
  METHODS: One hundred and seventy patients with angina pectoris and indications of coronary 
angiography underwent angiography. Serum levels of blood lipids, leptin, and adiponectin were 
measured.  The  gathered  data  was  evaluated  using  SPSS15  software,  by  multivariate  variance 
analysis. 
  RESULTS: Analysis of the data demonstrated that 45.1% of the patients had positive angio-
graphic findings. The serum levels of leptin and adiponectin were significantly lower than the 
minimum levels specified by the kit. However, the two groups, i.e., patients with positive angio-
graphic findings and those with negative findings were not significantly different according to 
the serum levels of the hormones. Moreover, no significant correlation between the serum levels 
of the hormones and serum lipids was observed. 
  CONCLUSION: Various studies have demonstrated that high serum level of leptin and the inci-
dence of coronary artery diseases are correlated. On the other hand, they have reported that 
adiponectin has cardioprotective role. Confirmation  of these findings requires  more detailed 
studies. 
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Introduction 
Today, cardiovascular diseases (CVD) are among the 
major causes of mortality throughout the world, and a 
significant  load  of  the  diseases  belongs  to  CVD.1,2 
Many preventive programs have focused on the con-
trol of these diseases, and the most important ones 
are addressing the issue of identification and reduc-
tion  of  the  risk  factors  of  CVD  incidence.  Main 
known  risk  factors  for  CVD  are  obesity,  hyperten-
sion, diabetes, and hyperlipidemia.3 Recent studies are 
seeking new and critical risk factors in incidence of 
ischemic  heart  diseases.  Some  of  these  factors  are 
lipoprotein Apo A and Apo B. However, some chem-
ical mediators have been discovered in blood, which 
are correlated with atherosclerosis and the incidence 
of coronary artery diseases (CAD). Leptin and adipo-
nectin are two of these chemical molecules, secreted 
by adipose tissue. Leptin is an amino acid discovered 
in 1994. Leptin deficiency is reported to be accompa-
nied by insulin resistance, obesity, diabetes, and even 
infertility in experimental models and human.4-6 Lep-
tin receptors exist in many tissues and play an impor-
tant role in metabolism of lipids and carbohydrates, as 
well  as  reproduction  system,  and  immune  and  in-
flammatory reactions.7 The role of leptin in the athe-
rosclerosis phenomenon is probably one of its signifi-
cant roles. The probable roles of leptin are as follows: 
First,  many  obese  individuals  have  a  hypothalamic 
resistance to leptin, which leads to an increase in lep-
tin  serum  level,  hyperleptinemia.  By  causing  endo-
thelial dysfunction, oxidative stress, platelet aggrega-
tion, and inflammatory reactions, hyperleptinemia will 
lead to atherosclerosis.8 Second, secretion of leptin by 
adipocytes is accompanied by an increase in insulin 
level, and insulin resistance. The relationship between   M. Mozafari, M. Sadeghi, H. Sanei, MA. Ramezani, A. Golabchi, N. Sarrafzadegan 
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hyperinsulinemia and insulin resistance, and atheros-
clerosis has been confirmed.9,10 Finally, it seems that 
leptin  causes  increased  sympathetic  nervous  system 
activity. Consequently, this leads to high blood pres-
sure and diabetes, which in turn causes an increase in 
incidence of atherosclerosis and CVD.11,12 Adiponec-
tin is opposite of leptin in many aspects. Adiponectin 
is also a hormone secreted from adipose tissue, which 
in  contrast  to  leptin  plays  an  anti-atherogenic  role. 
However, its serum level is lower in obese individuals, 
compared  with  those  with  normal  body  weight.  It 
leads  to  increased  sensitivity  to  insulin13,14  and  its 
blood level is higher in patients with Type 2 Diabetes 
and essential hypertension.15-17 Adiponectin receptors 
are found in peripheral tissues of skeletal system, GI 
system, liver, and endothelial cells.18 By inhibiting the 
effect of plaque forming inflammatory factors in en-
dothelial cells, adiponectin prevents development and 
progression of atherosclerosis, and considered a pro-
tective  factor  against  CAD.15  The  relationship  be-
tween secretion and physiological function of leptin 
and adiponectin has not been defined, but the impor-
tant issue is the ratio of leptin to adiponectin, which is 
considered as a risk factor for CAD.19 
  Nevertheless, most data were obtained in labora-
tory settings and there are few clinical data available in 
this regard. The objective of this study was to deter-
mine the relationship between the serum level of lep-
tin  and  adiponectin  in  patients  with  ischemic  heart 
diseases, as well as evaluation of the relationship be-
tween serum lipids and the two hormones. 
Method and Materials 
This was a cross-sectional study carried out on 170 
patients with stable angina pectoris, referred to Isfa-
han hospitals (Korshid Hospital and Shahid Chamran 
Hospital). Before beginning of the study, sample size 
was  determined  according  to  appropriate  statistical 
formulations. The patients were selected by easy sam-
pling  method  from  the  angiography  ward  of  the 
above-mentioned hospitals. Before performing coro-
nary angiography study, each patient attended an in-
terview session and his/her demographic data includ-
ing age, sex, occupation, education level, living place, 
marital status, and the work and home addresses were 
recorded. Then, the patients underwent physical ex-
amination and their height, weight, and blood pres-
sure were measured. The patients’ height was meas-
ured with bare foot using a height bar and the weight 
was measured using a calibrated standard scales. Pa-
tients’ blood pressure was measured by a calibrated 
sphygmomanometer with adult cuff in lying position 
from  their  right  hand.  The  patients  were  asked  to 
avoid having coffee and tea before physical examina-
tion, taking rest for at least 30 minutes, and not being 
anxious. Blood pressure was measured according to 
standard  blood  pressure  measurement  guideline.18 
The 10 cc venous blood sample taken from cubital 
vein of each patient was sent to the laboratory of Is-
fahan Heart Research Center for laboratory evalua-
tions. In the laboratory, blood cholesterol and trigly-
ceride (TG) were measured by Autoanalyzer (Hitachi), 
using  enzymatic  method,  high  density  lipoprotein 
(HDL) by precipitation with dextran sulfate, and low 
density lipoprotein (LDL) by Freidwald formulation 
method for patients with TG<400 and by direct me-
thod for those with TG>400. Also, leptin and adipo-
nectin were automatically measured by enzymatic me-
thod using proper kits (Pars Azma Co., Iran). Labora-
tory findings of each patient were recorded in a par-
ticular form. Then, the patients were referred for co-
ronary  angiography  and  underwent  complete  coro-
nary artery angiography. Involvement of any of the 
arteries  including  left  main  (LM),  left  anterior  des-
cending (LAD), left circumflex (LCx), right coronary 
(RC), and posterior descending (PD) arteries, and all 
their branches as well as the percentage of their in-
volvement  were  recorded.  Involvement  percentage 
higher than 50% in LM was scored two and involve-
ment of LAD, LCx, RCA, PDA, and their branches 
higher than 75% was scored one. If a patient had LM 
involvement, involvement of other arteries was not 
regarded. The overall arterial involvement was meas-
ured by multiplying the scores. The data was analyzed 
by SPSS15 software. The numerical data and nominal 
data were described using mean and standard devia-
tion, and frequency percentage, respectively, and t-test 
was used for mean comparisons. Considering the lep-
tin  and  adiponectin  alterations  in  different  ages  in 
both genders, linear variance analysis and ANCOVA 
models were used to eliminate the effect of age and 
gender. Pearson’s correlation coefficient was used to 
evaluate  the  correlation  among  numerical  variables. 
Level of significance was considered to be less than 
0.05 in all tests. 
Results 
Of 170 participants, six patients were excluded due to 
incomplete demographic and laboratory data; 74 pa-
tients (45.1%) of 164 cases were male. Mean age of 
the cases was 53.4 ± 7.6 years. The demographical 
characteristics of patients are presented in Table 1.  
 
 
 
 
 EVALUATION OF LEPTIN AND ADIPONECTIN 
52  ARYA Atherosclerosis Journal 2010 (Summer); Volume 6, Issue 2 
Table 1. Demographics characters of patients.  
Percent  Frequency  Variables 
 
45.1% 
54.9% 
 
74 
90 
Sex  
   Female  
   Male      
  53.7 (7.6)  Age mean (SD) 
 
0.6% 
83.5% 
3% 
12.8% 
 
1 
137 
5 
21 
Marital  Status  
   Single  
   Married     
   Divorced          
   Widow       
 
8% 
11% 
18.3% 
52.4% 
10.3% 
 
13 
18 
30 
86 
17 
Job 
   Employer 
   Worker 
   Self- employed 
   Housekeeper 
   Unemployed and Retired 
 
31.1% 
53% 
12.2% 
3.7% 
51 
87 
20 
6 
Education 
   Illiterate 
   Elementary   
   Diploma 
   University educated 
 
  Only 74 patients (45.1%), of all the cases who had 
stable angina and were candidate of coronary angio-
graphy had signs of coronary artery stenosis and 90 
patients did not have any signs indicative of coronary 
artery stenosis. Mean serum level of lipids and apo-
lipoproteins A and B of the two groups are separately 
provided  in  Table  2.  It  was  demonstrated  that  the 
mean level of blood lipids in the group with negative 
angiographic findings were lower compared with that 
of the group with positive findings. Comparison of 
the serum leptin and adiponectin levels as well as the 
ratio of leptin to adiponectin did not show any signif-
icant  difference  between  the  two  groups.  The  two 
groups were significantly different only regarding se-
rum  levels  of  total  cholesterol,  TG,  and  apo-
lipoproteins  A  and  B.  It  should  be  noted  that  the 
mean level of both leptin and adiponectin in patients 
was significantly lower than the minimum level speci-
fied for the kit; i.e., 15.1 ng/ml versus 26 ng/ml as 
the minimum level for leptin and 10.1 µg/ml versus 
14 µg/ml for adiponectin. Pearson’s correlation coef-
ficient  was  employed  to  evaluate  the  relationship 
among  leptin  and  adiponectin,  and  blood  levels  of 
lipids. The test did not find any correlation in this 
regard.  The  correlations  between  the  above-
mentioned variables are provided in Table 3. Consi-
dering the alteration of leptin and adiponectin level in 
different ages in two genders, linear variance analysis 
model ANCOVA was used to eliminate the effect of 
age and gender variables. However, the ratio of serum 
level of leptin to adiponectin and serum level of leptin 
and  adiponectin  was  not  significantly  different  be-
tween the two groups with positive and negative an-
giographic findings. Table 4 demonstrates the age and 
gender modified ratio of leptin to adiponectin. 
Discussion 
The results obtained in this study demonstrated that 
the mean serum level of leptin and adiponectin in the 
patients under study were significantly lower than the 
normal mean values specified in the standard kit. Non-
etheless, the two groups, groups with positive and neg-
ative angiographic findings, were not significantly dif-
ferent, even after being age and gender modified. Phy-
siological studies in animal models and human demon-
strated the independent effect of leptin and adiponec-
tin hormones on atherosclerosis.19 These studies consi-
dered a greater effect for leptin compared with adipo-
nectin or at least have considered the ratio of leptin to 
adiponectin as an independent risk factor for vascular 
dysfunction.12  
 
                      Table 2. Distribution of blood lipids in the two groups of study. 
P  t-test  Mean (SD)  group  variable 
0.005  2.88   200 (43.77)  Angiography (-)  TC (mg/dl) 
179.28 (47)  Angiography (+) 
0.04  2.042  194.67 (122.46)  Angiography (-)  TG(mg/dl) 
159.79 (93.35)  Angiography (+) 
  115 (31.46)  Angiography (-)   
0.09  1.697  106.36 (33)  Angiography (+)  LDL(mg/dl) 
0.05  1.976  32 (12.09)  Angiography (-)  HDL(mg/dl) 
35.56 (10.34)  Angiography (+) 
0.03  2.245  157.17 (26.94)  Angiography (-)  Apo-A 
147.69 (26.16)  Angiography (+) 
0.04  2.025  106.55 (25.63)  Angiography (-)  Apo-B 
97.73 (29.4)  Angiography (+)   M. Mozafari, M. Sadeghi, H. Sanei, MA. Ramezani, A. Golabchi, N. Sarrafzadegan 
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                           Table 3. Correlation coefficients between blood parameters and leptin and adiponectin. 
Leptin/Adiponectin  Adiponectin  Leptin  Variable 
-0.009  0.17*  0.08  Chol (mg/dl) 
0.06  0.001  0.12  TG (mg/dl) 
-0.05  0.12  -0.02  LDL (mg/dl) 
-0.12  0.31*  -0.04  HDL (mg/dl) 
0.07  0.15  0.16*   Apo A (mg/dl) 
0.04  0.08  0.05   Apo B (mg/dl) 
                      *P < 0.05 
In a clinical study, Dubey et al. confirmed that the 
serum level of leptin is patients with heart attack was 
significantly higher than that in patients with stable 
angina  and  normal  people.  They  also  demonstrated 
that leptin has significant correlation with inflamma-
tion mediators contributing to atherosclerosis. Serum 
level of leptin has significant positive correlation with 
C-reactive protein and interleukin 6.20 Previous stu-
dies have shown that inflammatory mediators have an 
important and confirmed role in formation of athe-
rosclerotic  plaques.  An  increase  in  these  mediators 
will lead to an increase in the incidence of CVD and 
these inflammatory mediators are considered as inde-
pendent risk factors for CAD.21 Being familiar with 
the effect of leptin on CAD, Wolk et al. carried out a 
study on the prognosis of patients with myocardial 
infarction (MI) in the US. They concluded that leptin 
level has a direct effect on the prognosis pf MI pa-
tients and those with higher levels of leptin had coro-
nary  artery  involvement  higher  than  50%  and  also 
their  number  of  involved  arteries  was  higher.22  In 
contrast to Wolk’s results, our results did not show a 
correlation between leptin serum level and the level of 
coronary artery involvement. The difference possibly 
originates from the difference between the types of 
studies. Our study was cross-sectional and not longi-
tudinal. Furthermore, we did not follow the patients’ 
prognoses  and our  only outcome  was  the  data  ob-
tained by coronary angiography. Since the levels of 
these  two  mediators  were  significantly  lower  than 
those in normal population, as specified by the kit, 
the following points should be considered. First, there 
is an important relationship among inflammatory me-
diators and the two hormones. A limitation of current 
studies, including the present study is not measuring 
the levels of these inflammatory mediators. Common 
relationship among the mediators and controlling the 
effect of each one may lead to more accurate results. 
  Additionally, all participants of this study had indi-
cation for coronary angiography by obvious clinical 
findings.  Although  we  categorized  the  patients  into 
the two groups of positive and negative angiographic 
findings,  the  classification  was  merely  based  upon 
involvement of coronary arteries specified in coronary 
angiography. Patients with normal coronary angiogra-
phy may have involvement of subepicardial or small 
vessels which cannot be found in coronary angiogra-
phy study. It is better to carry out longitudinal studies 
to evaluate the effects of leptin and adiponectin. By 
following  up  the  patients  and  performing  repeated 
measurement of the two hormones in such studies, 
and  also  recording  vascular  events  occurred  during 
the  patients’  follow-ups,  a  more  clear  relationship 
among the levels of the hormones and CAD will be 
found.  It  was  demonstrated  that  serum  leptin  level 
increases  significantly  after  MI,  and  the  increase  is 
detectable  during  the  acute  phase  of  MI.23  Recent
 
Table 4. Comparison of serum leptin and adiponectin in both groups with positive and negative angiography. 
Age and Sex Adjusted  t-test  Groups   
14.52 ± 1.4 
14.68 ± 1.53 
15 ± 1.43 
15.34 ± 1.8 
Angiography (+) 
Angiography (-) 
Leptin (ng/ml) 
11.21 ± 0.94 
8.88 ± 1.02 
10.89 ± 1 
9.23 ± 0.91 
Angiography (+) 
Angiography (-) 
Adiponectin (µg/ml) 
2.19 ± 0.34 
2.59 ± 0.37 
2.22 ± 0.34 
2.66 ± 0.4 
Angiography(+) 
Angiography (-) 
Leptin/ Adiponectin 
                 *No significant difference 
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studies have shown that adiponectin does not have a 
significant effect on heart diseases and there is not a 
relationship between adiponectin level and incidence 
and prognosis of coronary heart diseases.24-26 Moreo-
ver,  different  studies  have  confirmed  leptin  as  a 
strong predictor in cerebral vascular accidents (CVA), 
and have reported that serum leptin level is higher 
than normal in CVA patients.27-29 Considering adipo-
nectin, it should be noted that the higher levels of the 
hormone leads to the higher level of disability after 
CVA, which is in contrast with findings of other stu-
dies.30 Regarding the previous studies and the results 
of the present study, it is recommended to carry out 
longitudinal studies on CVD including patients with 
MI  and  CVA  with  repeated  measurement of  leptin 
and adiponectin. Results of cohort studies can clarify 
the relationship of the levels of the two chemical me-
diators and atherosclerosis. 
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